Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (Q35265979)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

13

object named as

Agnès Buzyn

0 references

Hervé Avet-Loiseau

3

object named as

Hervé Avet-Loiseau

0 references

Damien Roos-Weil

object named as

Damien Roos-Weil

1

0 references

Ibrahim Yakoub-Agha

object named as

Ibrahim Yakoub-Agha

15

0 references

7

object named as

Gérard Socié

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Philippe Moreau

2

object named as

Philippe Moreau

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

19

object named as

Didier Blaise

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

author name string

Jean-Louis Golmard

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Mathieu Kuentz

5

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Stéphane Vigouroux

6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sabine Furst

8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Jean Soulier

9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Steven Le Gouill

10

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sylvie François

11

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Anne Thiebaut

12

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Natacha Maillard

14

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Nicole Raus

16

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Jean-Paul Fermand

17

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Mauricette Michallet

18

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Nathalie Dhédin

20

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

21

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

96

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1504-1511

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

1994 Consensus Conference on Acute GVHD Grading

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

12 July 2018

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Clinical and biologic implications of recurrent genomic aberrations in myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

26 September 2018

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186312

15 November 2018

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Making progress in treating multiple myeloma with total therapies: issue of complete remission and more

1 reference

https://pubmed.ncbi.nlm.nih.gov/21685472

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2011.042713

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35265979&oldid=1861498441"